Sibylla Biotech

Sibylla Biotech is a groundbreaking biotech startup that emerged in 2017 as a spin-OFF of the INFN (National Institute of Nuclear Physics) and the Trento and Perugia Universities, based in Italy. The company's innovative approach to Early Drug Discovery focuses on developing new drugs to combat previously incurable diseases. Sibylla's pioneering technology, known as PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting), disrupts the folding process of proteins, leading to their degradation and selective reduction in expression levels. This approach has shown promise in the fields of oncology and antibiotic resistance, with potential applications in various therapeutic areas. The recent €23.00M Series A investment secured on 04 October 2022 highlights the confidence that VI Partners, 3B Future Health Fund, Indaco Venture Partners, Seroba Life Sciences, V-Bio Ventures, Vertis, Claris Ventures, and CDP Venture Capital have in Sibylla's innovative technology and its potential impact on the pharmaceutical industry. Additionally, the company's collaboration agreement with a notable Pharma company demonstrates its growing influence and partnership opportunities. Sibylla's dedication to developing proprietary computing technology showcases its commitment to pioneering innovation in drug discovery.